SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Wolden SL, Anderson JR, Crist WM, et al. Indications for radiotherapy and chemotherapy after complete resection in rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Studies I to III. J Clin Oncol. 1999; 17: 3468-3475.
  • 2
    Regine WF, Fontanesi J, Kumar P, et al. Local tumor control in rhabdomyosarcoma following low-dose irradiation: comparison of group II and select group III patients. Int J Radiat Oncol Biol Phys. 1995; 31: 485-491.
  • 3
    Michalski JM, Meza J, Breneman JC, et al. Influence of radiation therapy parameters on outcome in children treated with radiation therapy for localized parameningeal rhabdomyosarcoma in Intergroup Rhabdomyosarcoma Study Group trials II through IV. Int J Radiat Oncol Biol Phys. 2004; 59: 1027-1038.
  • 4
    Douglas JG, Arndt CA, Hawkins DS. Delayed radiotherapy following dose intensive chemotherapy for parameningeal rhabdomyosarcoma (PM-RMS) of childhood. Eur J Cancer. 2007; 43: 1045-1050.
  • 5
    Smith SC, Lindsley SK, Felgenhauer J, Hawkins DS, Douglas JG. Intensive induction chemotherapy and delayed irradiation in the management of parameningeal rhabdomyosarcoma. J Pediatr Hematol Oncol. 2003; 25: 774-779.
  • 6
    Eaton B, Katzenstein H, Sutter A, et al. Delayed radiation therapy timing and use of intensity-modulated radiation therapy in non-head and neck pediatric rhabdomyosarcoma [published online ahead of print July 20, 2012]. J Radiat Oncol. 2012.
  • 7
    Lin C, Donaldson SS, Meza JL, et al. Effect of radiotherapy techniques (IMRT vs 3D-CRT) on outcome in patients with intermediate-risk rhabdomyosarcoma enrolled in COG D9803—a report from the Children's Oncology Group. Int J Radiat Oncol Biol Phys. 2012; 82: 1764-1770.
  • 8
    McDonald MW, Esiashvili N, George BA, et al. Intensity-modulated radiotherapy with use of cone-down boost for pediatric head-and-neck rhabdomyosarcoma. Int J Radiat Oncol Biol Phys. 2008; 72: 884-891.
  • 9
    Wolden SL, Wexler LH, Kraus DH, Laquaglia MP, Lis E, Meyers PA. Intensity-modulated radiotherapy for head-and-neck rhabdomyosarcoma. Int J Radiat Oncol Biol Phys. 2005; 61: 1432-1438.
  • 10
    Curtis AE, Okcu MF, Chintagumpala M, Teh BS, Paulino AC. Local control after intensity-modulated radiotherapy for head-and-neck rhabdomyosarcoma. Int J Radiat Oncol Biol Phys. 2009; 73: 173-177.
  • 11
    Chen C, Shu HK, Goldwein JW, Womer RB, Maity A. Volumetric considerations in radiotherapy for pediatric parameningeal rhabdomyosarcomas. Int J Radiat Oncol Biol Phys. 2003; 55: 1294-1299.
  • 12
    Lawrence W Jr, Gehan EA, Hays DM, Beltangady M, Maurer HM. Prognostic significance of staging factors of the UICC staging system in childhood rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study (IRS-II). J Clin Oncol. 1987; 5: 46-54.
  • 13
    Maurer HM, Beltangady M, Gehan EA, et al. The Intergroup Rhabdomyosarcoma Study-I. A final report. Cancer. 1988; 61: 209-220.
  • 14
    Raney RB, Maurer HM, Anderson JR, et al. The Intergroup Rhabdomyosarcoma Study Group (IRSG): major lessons from the IRS-I through IRS-IV studies as background for the current IRS-V treatment protocols. Sarcoma. 2001; 5: 9-15.
  • 15
    Punyko JA, Mertens AC, Gurney JG, et al. Long-term medical effects of childhood and adolescent rhabdomyosarcoma: a report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer. 2005; 44: 643-653.
  • 16
    Raney RB, Asmar L, Vassilopoulou-Sellin R, et al. Late complications of therapy in 213 children with localized, nonorbital soft-tissue sarcoma of the head and neck: a descriptive report from the Intergroup Rhabdomyosarcoma Studies (IRS)-II and IRS-III. IRS Group of the Children's Cancer Group and the Pediatric Oncology Group. Med Pediatr Oncol. 1999; 33: 362-371.
  • 17
    Paulino AC, Simon JH, Zhen W, Wen BC. Long-term effects in children treated with radiotherapy for head and neck rhabdomyosarcoma. Int J Radiat Oncol Biol Phys. 2000; 48: 1489-1495.
  • 18
    Merchant TE, Goloubeva O, Pritchard DL, et al. Radiation dose-volume effects on growth hormone secretion. Int J Radiat Oncol Biol Phys. 2002; 52: 1264-1270.
  • 19
    Merchant TE, Rose SR, Bosley C, Wu S, Xiong X, Lustig RH. Growth hormone secretion after conformal radiation therapy in pediatric patients with localized brain tumors. J Clin Oncol. 2011; 29: 4776-4780.
  • 20
    Childs SK, Kozak KR, Friedmann AM, et al. Proton radiotherapy for parameningeal rhabdomyosarcoma: clinical outcomes and late effects. Int J Radiat Oncol Biol Phys. 2012; 82: 635-642.
  • 21
    Maurer HM, Gehan EA, Beltangady M, et al. The Intergroup Rhabdomyosarcoma Study-II. Cancer. 1993; 71: 1904-1922.
  • 22
    Crist W, Gehan EA, Ragab AH, et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol. 1995; 13: 610-630.